Cerebral vasomotor reactivity in the acute phase and after 6 months in non-disabling stroke/TIA: A prospective cohort study

•VMR in the acute phase does not differ among different stroke subtypes.•VMR is higher in the acute phase than at 6 months in patients with non-disabling stroke/TIA.•The higher VMR in the acute phase could be sustained by an increased Cerebral Blood Flow. Cerebral Vasomotor Reactivity (VMR) is a pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of stroke and cerebrovascular diseases 2024-09, Vol.33 (9), p.107841, Article 107841
Hauptverfasser: Brunelli, Nicoletta, Altamura, Claudia, Marcosano, Marilena, Rossi, Sergio Soeren, Costa, Carmelina Maria, Fallacara, Adriana, Bach-Pages, Marcel, Silvestrini, Mauro, Mallio, Carlo Augusto, Vernieri, Fabrizio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•VMR in the acute phase does not differ among different stroke subtypes.•VMR is higher in the acute phase than at 6 months in patients with non-disabling stroke/TIA.•The higher VMR in the acute phase could be sustained by an increased Cerebral Blood Flow. Cerebral Vasomotor Reactivity (VMR) is a property of cerebral hemodynamics that protects from cerebrovascular disease. We aimed to explore the VMR longitudinal changes in patients with acute non-disabling stroke/Transient Ischemic Attack (TIA) to understand its implication in stroke ethiopatogenesis. VMR by Transcranial Doppler Breath Holding test was performed at 48-72 h from stroke onset (T1) and after 6 months (T2) on MCA of the non-affected hemisphere and PCA of the affected hemisphere. We consecutively enrolled 124 patients with a median age of 66.0 (IQR 54.75-74.25) years with a median NIHSS 2 (IQR 1-3). Both MCA (1.38 %/s SD 0.58) and PCA (1.35 %/s SD 0.75) BHI at T1 did not differ among different stroke subtypes (p=0.067 and p=0.350; N=124). MCA and PCA BHI decreased from T1 to T2 (respectively 1.39 %/s SD 0.56 vs 1.18%/s SD 0.44 and 1.30 %/s SD 0.69 vs 1.20 %/s SD 0.51; N=109) regardless of ethiopatogenesis (respectively p
ISSN:1052-3057
1532-8511
1532-8511
DOI:10.1016/j.jstrokecerebrovasdis.2024.107841